Belvedere Trading’s Inhibrx INBX Stock Holding History

Belvedere Trading’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,402	Closed	-$585K	–	863
2025 Q4	$585K	Buy	7,402 +1,125	+18%	+$76.7K	﹤0.01%	256
2025 Q3	$211K	Buy	+6,277	New	+$155K	﹤0.01%	470

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Belvedere Trading's INBX Position: Q1 2026 in Review

Belvedere Trading sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 7,402 shares — an estimated $585K sold.

Belvedere Trading first reported a position in INBX in Q3 2025 and held it in 2 quarters. The position peaked at $585K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Belvedere Trading reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
Belvedere Trading sold 7,402 Inhibrx shares in Q1 2026, an estimated $585K.
Belvedere Trading first reported a position in Inhibrx in Q3 2025 and held it in 2 quarters.
Belvedere Trading's Inhibrx position peaked at $585K in Q4 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.